Lexaria Bioscience Corp

Lexaria Bioscience, Nuka Enterprises expand relationship to rapidly grow market for Nuka’s 1906 edibles brand

Over the next two years, 1906 is expanding its premium edibles, which combine cannabis and plant medicines, to key legal markets including Illinois, Ohio, Massachusetts and Michigan

1906 edibles
Lexaria has developed and out-licenses its disruptive DehydraTECH technology

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) announced Tuesday that the “most reliable, fast-acting edibles” on the market will now be available across the country through a major expansion in operations by Nuka Enterprises LLC, maker of 1906 cannabis edibles for adults.

Last year, Nuka acquired contractual options to expand its use of Lexaria’s DehydraTECH technology which delivers cannabinoids (CBD) to the bloodstream more quickly and effectively than conventional industry CBD edible formulations.

Exercising some of those options, Nuka plans to expand operations for cannabis chocolates and edibles in six additional states and cannabis beverages in three states in 2019 and 2020.

READ: Lexaria’s DehydraTECH formulation delivers over tenfold CBD to bloodstream than conventional industry formulations

“As the fastest growing edibles brand in Colorado, we believe a huge part of our consumer appeal is because of this fast-acting technology,” said Nuka Enterprises co-founder and CEO Peter Barsoom in a statement. “We look forward to continuing to innovate alongside Lexaria, whose technology is the best in the industry.”

Currently, 1906 offers six distinct formulations that combine low-dose cannabis with targeted plant medicines. Over the next two years, 1906 is expanding its product offerings to other legal markets including: Illinois, Ohio, Massachusetts, and Michigan. Overall, roughly a ten-fold increase in product volumes manufactured by Nuka utilizing DehydraTECH is expected over the next 18 months.

As part of its mission to bring cannabis back to its pre-prohibition status as widely used medicine, Nuka says it will also begin using DehydraTECH to create consumer products containing CBD.

Breakthough CBD technology

Lexaria’s DehydraTECH formulation delivers over a tenfold amount of CBD to the bloodstream than conventional industry formulations.

The company recently announced that animal testing proved its flagship DehydraTECH technology delivers 475% more CBD to the bloodstream in 15 minutes than other standard industry formulations that combine CBD with medium chain triglyceride (MCT) oils such as coconut oil.

Nuka has utilized Lexaria’s technology within its award-winning 1906 chocolates for roughly three years. Since its founding three years ago, 1906 has advanced from a start-up to Colorado’s fastest growing edibles company, whose products are now available in more than 200 dispensaries.

Semi-exclusive agreement

The semi-exclusive agreement provides Nuka and 1906 with competitive technological advantages until 2028, as well as growing revenue streams for Lexaria. A second license provides Nuka and 1906 with the immediate ability to utilize DehydraTECH technology for CBD across the US marketplace.

“Nuka’s astonishing growth since launch is impressive and we can’t wait to see what innovative products they design next using DehydraTECH technology,” said Lexaria Bioscience CEO Chris Bunka. “Together, we have a market advantage that will significantly change public perception of how and when to consume cannabis and plant medicine because consumers don’t have to wait an hour, or longer for their edibles to kick in with the 1906 brand.”

On April 30, 2018, Lexaria announced that Nuka had also acquired an option to expand its products and brand to Canada and across the US. Nuka and 1906 plan to leverage the competitive advantages of Lexaria’s DehydraTECH across multiple product lines including edibles and topical products.

DehydraTECH, according to Lexaria, increases intestinal absorption, speeds delivery to the bloodstream and provides taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.

The Kelowna, British Columbia-based company’s disruptive DehydraTECH technology can be applied to foods, beverages, oral suspensions, tablets and capsules.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: Lexaria Bioscience Corp

Price: $0.89

Market: CSE
Market Cap: $69.99 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp named herein, including the promotion by the Company of Lexaria Bioscience Corp in any Content on the Site, the Company...



Lexaria Bioscience sees positive results from study using DehydraTECH Technology

Lexaria Bioscience (CSE:LXX-OTCQX:LXRP) President John Docherty joined Steve Darling from Proactive Investors Vancouver to talk about a recent controlled, double-blinded European human clinical study that evaluated TurboCBD, Lexaria’s  DehydraTECH powered, cannabidiol fortified hemp-oil...

on 23/2/19

3 min read